Showing results (191-200 of 462) with videos related to

Sort By:
Pageof 47
Perfusion|September 1, 1995
The blood saving potential of vortex versus roller pump with and without aprotininA Wahba, A Philip, M F Bauer, et al.
Medicine and Science in Sports and Exercise|December 1, 1990
Differences in epinephrine and substrate responses between arm and leg exerciseS P Hooker, C L Wells, M M Manore, et al.
Cancer|July 29, 2009
Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literatureAhmed O Kaseb, Amr Hanbali, Matthew Cotant, et al.
Cancer|October 24, 2007
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumorShirish M Gadgeel, Shadan Ali, Philip A Philip, et al.
Carcinogenesis|March 1, 1988
Polymorphic N-acetylation capacity in lung cancerP A Philip, D L Fitzgerald, R A Cartwright, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|July 20, 2011
Expression of microRNAs: potential molecular link between obesity, diabetes and cancerA S Ali, S Ali, A Ahmad, et al.
Carcinogenesis|May 29, 2012
Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancerOmar Soubani, Azfur S Ali, Farah Logna, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 23, 1999
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factorP A Philip, D Rea, K Mitchell, et al.
Critical Reviews in Oncology/Hematology|March 21, 2012
Metabolomics in cancer: a bench-to-bedside intersectionWederson M Claudino, Priscila H Goncalves, Angelo di Leo, et al.
Expert Opinion on Therapeutic Targets|April 30, 2010
PAR-4 as a possible new target for pancreatic cancer therapyAsfar S Azmi, Philip A Philip, Syed F Zafar, et al.
Pageof 47